ArticleFrontiers in oncology2026

Durable complete response to pembrolizumab after BRAF/MEK inhibition in recurrent MSI-H/dMMR, BRAF V600E-mutant colon cancer: a case report.

Wenyan Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.